Get started
Clover Health Investments, Corp.Clover Health Investments, Corp.Clover Health Investments, Corp.

Clover Health Investments, Corp.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CLOV trade ideas

Clover Health Rallies Despite An Early Sell-off Into A $6.31 LowThe movement of $CLOV continues to mirror the condition of the overall market. Today, the tech-led sell-off took a pause, with S&P 500 rising by 1.95% and NASDAQ Composite rising by 1.55%. Similarly, Clover Health ended higher by 7.54%, closing above the previous day's close. Going into next week, I expect $CLOV performance to continue reflecting the overall market condition. Nevertheless, these are some notable resistance and support area that you should take note next week, with key areas highlighted in Bold: Psychological resistance: $8.00 , $8.50 , $9.00 Psychological support: $7.50, $7.00, $6.50 , $6.00 Fibonacci resistance: $9.92 Fibonacci support: $7.78, $6.67 , $5.07 Dynamic resistance: Bottom of the previous bearish channel that we were trading in before this market correction ( ~$8.50 ) Dynamic support: Top of the very tight bearish channel that we just broke out of (~$7.10) Once this correction is over, I expect $CLOV to emerge as one of the winners. Invest safe. This is not investment advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
6
$CLOV Finding The BottomThe bearish channel has broken to the downside and we are now in an unchartered territory. Within this unchartered territory, I expect every $0.50 to be a new support (i.e. $8.50, $8.00, $7.50, $7.00, and so on). As of the time that I am writing this post, we have broken the $8.50 support and found a $8.03 low. It will be difficult to predict where we will find a bottom, but what I can tell you is that $CLOV is severely undervalued at this price. It was undervalued at $10, it is undervalued at $8.00, and it will still be undervalued if it dips below $8.00. $CLOV recent earnings, albeit slower than expected, has proved that it is capable of growth. This will be a winner further down the road. However, if you are in this for a quick buck, $CLOV is not for you. But if you are an investor, do your fullest DD, strengthen your resolves, and buckle your seatbelts, because you are in for a rollercoaster ride until the negative sentiment surrounding $CLOV settles down. Regardless, $CLOV will be a winner for long-term investors. Chamath Palihapitiya once said in a CNBC interview that Clover Health will be their next 10x in 10 years investment, and I truly believe $CLOV is capable of it. This is not investment advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
CLOV Retracement, Massively Oversold but Needs PRCLOV has not received much love these past few weeks after the short report from Hindenburg came out, but I believe that the short report does not hold much substance as well as the fact that CLOV had posted phenomenal earnings. CLOV stock had dropped about 12% after reporting great earnings but weak guidance for 2021. CLOV is also being investigated by the DOJ due to the short report which has created a lot of uncertainty for the stock. But all of these variables do not discredit the fact that CLOV has been massively beaten down along with having great earnings. I see CLOV most likely trading sideways until the DOJ investigation is over. Any type of good PR for CLOV will send the stock skyrocketing with immense upside, but if the DOJ investigation materializes into anything, CLOV's stock price might be sent down into the 5s. Key support for CLOV is 9$ and then 8.50$. My prediction for CLOV is it having a short-term spike up to 9.70$ then bottoming out in the low 9s. This is not financial advice, I am not advocating the buying or selling of CLOV stock.
NASDAQ:CLOVLong
by kediguy
$CLOV Earnings OutlookFrom 2019 to 2020, $CLOV posted a total revenue growth from $462.3M to $672.9M, net premium revenue growth from $456.9M to $665.7M, decrease in net loss from -$363.7M to -$91.6M, and a decrease in adjusted EBITDA loss from -$175.5M to -$74.4M, among others. $CLOV also saw a 36.3% increase in membership and a 43.2% year-over-year increase in lives under Clover Assistant management to 58,056 membership and over 32,400 lives respectively. For full year 2021 guidance, $CLOV stated a total revenue expectation of $820M to $850M, net loss expectation of -$210M to -$170M, adjusted EBITDA loss expectation of -$190M to -$150M, loss per share of -$0.52 to -$0.42. Furthermore, they are also expecting a 17% to 21% growth in Medicare Advantage membership to 68,000 to 70,000 membership compared to year end 2020's 58,056. Based on the above full year 2020 financial results and full year 2021 guidance reported by Clover Health, I believe it puts us somewhere in the middle of our bear case and base case as said according to our last $CLOV Bear Base Bull outlook, which you can re-visit by looking at the related idea below. In my opinion, despite being off-target, the financial and membership growth that they have posted from 2019 to 2020 has demonstrated their ability to deliver growth, proven the scalability of their business model, and reaffirmed Chamath Palihapitiya statement of $CLOV having a predictable growth model. However, I believe they have shot themselves in their foot with the full year 2021 guidance. Based on the figures they have posted, it tells me that they are expecting a slowdown in growth compared to what they have experienced from 2019 to 2020. This will not be viewed kindly by investors and Wall Street. Going forward, I expect $CLOV to continue trading within the bearish channel, within the range of $8.50 to $10.50. Unless further positive catalyst appears, I do not see $CLOV breaking above the bearish channel yet. Nevertheless, in an environment where many SPAC and companies are trading at a massive speculative values, I see $CLOV being valued realistically at the moment and trading at a realistic price. Once given enough time to play out the growth that $CLOV is currently building, it will be a long-term winner. TLDR: Short-term: Underperform with a trading range of $8.50 to $10.50 unless more positive catalyst appears, Mid/Long-term: Easily >2x from current price. This is not investment advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
7
CLOV - There's absolutely NO SHOT..... right?Alright, so hear me out. NASDAQ:CLOV has this insane, speculative expanding wedge/triangle pattern forming. I mean, there's absolutely NO SHOT this can actually play out. It HAS to be just a coincidence...... right? The featured content is intended to be used for informational purposes only. Everything shared here is my own opinion. It is very important to do your own analysis before making any investment based on your own personal circumstances.
NASDAQ:CLOVLong
by jstrasburger
9
$CLOV Bear Base Bull Outlook$CLOV continues to move within the symmetrical triangle while being encapsulated by a bearish channel. As we approach the end of the symmetrical triangle, I am expecting a breakout to by next week, as early as Monday. I believe the upcoming earnings on 03/01/2021's post-market to be a major catalyst to which direction the breakout will be. Bear Case: In the event that we get a negative earnings surprise, $CLOV will be headed further down into unchartered territory. The sell-off will likely be exacerbated by weakening market conditions and the lack of PR by Chamath Palihapitiya, Vivek Garipalli, and Clover Health Corp. Throw in the FUD created by the Hidenburg Research's short-seller report, and you have a recipe for a sell-off into the $7 and $8 territory. How soon we recovery from that will likely depend on the impact of the fiscal stimulus, whether there are any positive news released by Clover/Chamath/Vivek, and how long it takes for the short-seller report to be cleared up by the SEC. Base Case: Earnings data come out as expected and there was no deviation compared to what was expected. Due to technical factors such as RSI pointing towards $CLOV being incredibly oversold, volume picking up again, and $CLOV currently being in an area of multiple huge support level, we see a push back to the dynamic resistance of the bearish channel. However, breaking above could prove to be challenging without positive sentiments around $CLOV. We might start consolidating between $10 to $11 or even re-test the dynamic support of the bearish channel. Bull Case: Clover Health Corp releases a positive earnings surprise and Clover/Chamath/Vivek takes the opportunity to boost PR to create more positive sentiments around $CLOV. The aforementioned, supported by bullish technical indicators, pushes $CLOV back to the dynamic resistance of the bearish channel, subsequently breaking beyond it and holding above the bearish channel. As the fiscal stimulus comes in, we see money flowing into the stock market, and $CLOV continue to grow towards $14 and beyond. TLDR: $7-$8 Bear Case, $10-$11 Base Case, >$14 Bull Case. This is not investment advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
6
CLOV (final idea)MID-TERM: 1hr classic bullish divergence, 4hr classic bullish divergence, daily hidden bullish divergence, bullish gartley harmonic pattern, support area being created, bullish candle signals. (not financial advice) ***My original idea here was wrong and I admit that, it's a combination of the market volatility this week and all the bagholders selling bounces. The sign of life today gives me more confidence, this just feels so similar to when I posted $FSR at $9 (went to $23) and when I posted $QS at $47 (went to $70).
NASDAQ:CLOVLong
by Champion-Vibe
3
$CLOV $14 Recovery PlayAfter being hit by a short-seller report published by Hindenburg Research on 02/04/2021, we saw $CLOV share price declining steadily up till the current value of $10.98 as of closing price Friday. Clover Health Investments Corp is a company that operates as a Medicare Advantage insurer in the United States by providing preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers through its software platform - Clover Assistance. It is backed by Chamath Palihapitiya who has brought $CLOV public through a reverse merger with IPOC. I believe at the current price that the share is trading at, $CLOV is an absolute bargain that is well-positioned for a recovery play with a great risk/reward ratio. I expect any dips into the $9.87 to $10.50 demand zone to be bought up rapidly by buyers who are looking to load up on $CLOV shares - which should translate to rapid bounce back of price off the demand zone. This held true on Thursday and Friday where we saw $CLOV temporarily dipping to $10.50, only to recover rapidly from that level. I foresee $CLOV recovering steadily back to $14.10 once the negative sentiment created by the short-seller report starts fading away. The only reason why I am not putting my price target any higher than $14.10 for the time being is because I see the level between $14.13 and $17.22 to be an area of strong supply zone. However, if we are able to break above the supply zone, I believe that it is perfectly reasonable for $CLOV to be trading at shy of $20.00. But for the time being, my target is $14.10. Please set SL based on your own risk tolerance. This is not investment advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
2